U.S. stock indices slump amid tariff talks while healthcare sees major developments: J&J faces a $1.6B lawsuit, new FDA approvals, and a $2B ...
We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
A new antibiotic has been approved to treat urinary tract infections by the Food and Drug Administration for the first time ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir ...
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
The approval was based on data from two late-stage trials showing the drug was superior to nitrofurantoin, the ...
A 10% surge in child TB infections in Europe has prompted urgent WHO action, European regulators are evaluating GSK's drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback